Advertisement

Topics

XENON Xe 133 GASFOR DIAGNOSTIC USE |

05:38 EDT 27th August 2014 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

XENON Xe 133 Gas is supplied in a mixture of xenon gas (5%) in carbon dioxide (95%). It is contained within septum sealed glass vials and is suitable for inhalation in the diagnostic evaluation of pulmonary function and imaging, as well as assessment of cerebral blood flow. Xenon Xe 133 Gas is reactor-produced as a by-product of Uranium U235 fission. Each vial contains the labeled amount of Xenon Xe 133 radioactivity at the time of calibration. The contents of the vial are in gaseous form, contain no preservatives, and are ready for use.

Xenon Xe 133 is chemically and physiologically related to elemental Xenon, a non-radioactive monoatomic gas which is physiologically inert except for anesthetic properties at high doses.

Xenon Xe 133 decays by beta and gamma emissions with a half-life of 5.245 days. Significant radiations which are emitted by the nuclide are listed in Table 1.

Table 1. Principal Radiation Emission Data from Xenon-133
MeanMean % per
RadiationEnergy (KeV)Disintegration
Beta-2100.699.3
Ce-K-245.053.3
Ce-L-275.38.1
Ce-M-279.81.7
Gamma-281.036.5
Kα2X-ray30.613.6
Kα1X-ray31.025.3
KβX-ray35.09.1

The specific gamma ray constant for Xenon Xe 133 is 3.6 microcoulombs/Kg-MBq-hr (0.51R/hr-mCi) at 1 cm. The first half value thickness of lead is 0.0035 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from the interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.20 cm of Pb will decrease the external radiation exposure by a factor of 1,000.

To correct for physical decay of this radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

Table 2. Radiation Attenuation by Lead Shielding
cm of PbRadiation Attenuation Factor
0.00350.5
0.03710-1
0.1210-2
0.2010-3
0.2910-4
Table 3. Xenon Xe 133 Physical Decay Chart (Half Life 5.245 days)
FractionFraction
DayRemainingDayRemaining
0Calibration Day1.0008.349
1.8779.302
2.76810.268
3.67411 .235
4.59112.206
5.51813.181
6.45214.157
7.398

Xenon Xe 133 is a readily diffusible gas which is neither utilized nor produced by the body. It passes through cell membranes and freely exchanges between blood and tissue. It tends to concentrate more in body fat than in blood, plasma, water or protein solutions. In the concentrations used for diagnostic purposes it is physiologically inactive. Inhaled Xenon Xe 133 Gas will enter the alveolar wall and enter the pulmonary venous circulation via the capillaries. Most of the Xenon Xe 133 that enters the circulation from a single breath is returned to the lungs and exhaled after a single pass through the peripheral circulation.

Inhalation of Xenon Xe 133 Gas has proved valuable for the evaluation of pulmonary function and for imaging the lungs. It may also be applied to assessment of cerebral flow.

None known.

Xenon Xe 133 Gas delivery systems, i.e., respirators or spirometers, and associated tubing assemblies must be leakproof to avoid loss of radioactivity into the environs not specifically protected by exhaust systems.

Xenon Xe 133 adheres to some plastics and rubber and should not be allowed to stand in tubing or respirator containers. The unrecognized loss of radioactivity from the dose for administration may render the study non-diagnostic.

Xenon Xe 133, as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to patients consistent with proper patient management.

Exhaled Xenon Xe 133 gas should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of radionuclides.

Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorized to license the use of radionuclides.

No long term animal studies have been performed to evaluate carcinogenic potential or whether Xenon Xe 133 affects fertility in males or females.

Animal reproductive studies have not been conducted with Xenon Xe 133 Gas. It is also not known whether Xenon Xe 133 Gas can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Xenon Xe 133 Gas should be given to a pregnant woman only if clearly needed.

Ideally, examination using radiopharmaceuticals, especially those elective in nature in a woman of childbearing capability, should be performed during the first few (approximately 10) days following the onset of menses.

It is not known whether Xenon Xe 133 is excreted in human milk. Many drugs are excreted in human milk, therefore formula feedings should be substituted for breast feeding, because of the potential for adverse reactions in nursing infants.

Safety and effectiveness in the pediatric population has not been established.

Clinical studies of Xenon Xe 133 Gas did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Adverse reactions related to the use of this agent have not been reported to date.

Xenon Xe 133 gas is administered by inhalation from closed respirator systems or spirometers.

The suggested activity range employed for inhalation by the average adult patient (70 kg) is:

Pulmonary function including imaging: 74-1110MBq (2-30mCi) in 3 liters of air.

Cerebral blood flow: 370-1110MBq (10-30mCi) in 3 liters of air.

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

The estimated absorbed radiation doses to an average patient (70 kg) for pulmonary perfusion and cerebral blood flow studies from a maximum dose of 1110 MBq (30mCi) of Xenon Xe 133 in 3 liters of air are shown in Table 4.

Table 4. Radiation Doses
EffectiveWhole
Half-TimeLungs99% of activity is in lungs.BrainBody
mGy/1110MBq (rads/30mCi)
Pulmonary
   Perfusion

2 min.

2.5(0.25)

0.014(0.0014)

0.027(0.0027)
Cerebral
   Flow

5 min.

6.3(0.63)

0.035(0.0035)

0.068(0.0068)

The Xenon Xe 133 gas is supplied as part of the Calidose™ system, consisting of 3ml unit dose vials and the Calidose dispenser* for shielded dispensing.

Normally vials containing either 370 or 740MBq (10 or 20mCi)/vial, packed up to 5 vials per shield tube, are supplied. Vial sets containing up to 3700MBq (100mCi)/vial are available.

The NDC number for: 10mCi vial is 11994-127; 20mCi vial is 11994-128; 30mCi vial is 11994-129; 40mCi vial is 11994-130; 50mCi vial is 11994-131; 100mCi vial is 11994-133.

Store at controlled room temperature 20°-25°C (68°-77°F) [See USP].

This radiopharmaceutical is approved for distribution to persons licensed pursuant to the Code of Massachusetts Regulations 105 CMR 120.100 for the uses listed in 105 CMR 120.533 or under equivalent licenses of the U.S.Nuclear Regulatory Commission, an Agreement State, or a Licensing State.

The contents of the vial are radioactive. Adequate shielding and handling precautions must be maintained.

Bristol-Myers SquibbMedical Imaging

331 Treble Cove Rd., N. Billerica, MA 01862 USAFor Ordering Tel. Toll Free 800-225-1572(For Massachusetts and International, Call 978-667-9531)All Other Business 800-362-2668

Printed in U.S.A.

515083-0303 March 2003

Manufacturer

Bristol Myers Squibb Foundation

Active Ingredients

Source

Clinical Trials [149589 Results]

The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery

Arnica montana is a homeopathic drug that is made in accordance with the official methods of the Homeopathic Pharmacopoeia of the United States (HPUS) and is commonly used by cosmetic surg...

Pharyngeal Size in Patients With Obstructive Tonsils Under Orthodontic Treatment

Enlarged tonsils and malocclusion has relationship with sleep disturbance in children. The consequences of these features can include aggravation of craniofacial growth such that the devel...

The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response

The purpose of this study is to assess the effects of repeated RIPC and exercise, on exercise performance, skeletal muscle responses and circulating cellular and humoral biology in humans

Pilot Study of Raltegravir Lipodystrophy IISP

The substitution of raltegravir for the NRTIs will result in some reversal of the long term adverse effect of lipodystrophy (specifically peripheral lipoatrophy) that is associated with th...

Esophagoscopy in Evaluating Treatment in Patients With Stage I-IV Head and Neck Cancer Who Are Undergoing Radiation Therapy and/or Chemotherapy

Brief Summary: RATIONALE: Comparing results of diagnostic procedures, such as esophagoscopy, done before and after radiation therapy and/or chemotherapy may help doctors predict a patient...

PubMed Articles [1001009 Results]

Decreased complexity of glucose dynamics preceding the onset of diabetes in mice and rats.

Continuous glucose monitoring (CGM) is a platform to measure blood glucose (BG) levels continuously in real time with high enough resolution to document their underlying fluctuations. Multiscale entro...

Adherence to 6-Mercaptopurine in children and adolescents with Acute Lymphoblastic Leukemia.

Studies on children with Acute Lymphoblastic Leukemia (ALL) reported non-adherence in 2-54% of cases. The primary objective of this study was to assess rates of adherence to 6-MP using two different m...

To be on the safe site - Ungroomed spots on the bee's body and their importance for pollination.

Flower-visiting bees collect large quantities of pollen to feed their offspring. Pollen deposited in the bees' transport organs is lost for the flowers' pollination. It has been hypothesised that spec...

Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.

Cryptococcal meningitis is one of the leading causes of death among people with HIV in Africa, primarily due to delayed presentation, poor availability and high cost of treatment. Routine cryptococcal...

Motion-based video monitoring for early detection of livestock diseases: The case of African swine fever.

Early detection of infectious diseases can substantially reduce the health and economic impacts on livestock production. Here we describe a system for monitoring animal activity based on video and dat...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Anesthesia
Anesthesia is the loss of feeling or sensation in all or part of the body. It may result from damage to nerves or can be induced by an anesthetist (a medical professional) using anesthetics such as thiopental or propofol or sevoflurane during a surgical ...

Radiology
Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record